Review



pam 3 csk 4  (InvivoGen)


Bioz Verified Symbol InvivoGen is a verified supplier
Bioz Manufacturer Symbol InvivoGen manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 99
      Buy from Supplier

    Structured Review

    InvivoGen pam 3 csk 4
    Six-weeks-old C57BL/6 male mice were mock-transduced or transduced with 10 11 ⍰vge of AAV-HBV 1.3 mer genotype D/serotype ayw for 31 days to allow establishment of chronic infection. At day-35, treatment cycles were started, after mice were evenly grouped according to viremia and HBsAg antigenemia. Mice (n⍰= ⍰7/group) were injected, at indicated days with vehicle (PBS), free/non vectorized <t>Pam</t> <t>3</t> <t>CSK</t> <t>4</t> at 100 μg/injection, NP-Pam 3 CSK 4 at 5 μg/shot, or NP-Pam 3 CSK 4 at 20 μg/shot. 3TC was administrated continously at approximately 100 mg/kg/day (in drinking water) between days-35 and 64 and days-79 and 90. Blood/serum was collected at indicated times (blood drop symbol). Mice were euthanized at 90 days post-transduction. The different readouts and used techniques for exploitation of blood and liver samples are indicated.
    Pam 3 Csk 4, supplied by InvivoGen, used in various techniques. Bioz Stars score: 99/100, based on 3712 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/pam+3+csk+4/Pam3CSK4/bio_rxiv__64898__2026__05__27__728102-37-1-5
    Average 99 stars, based on 3712 article reviews
    pam 3 csk 4 - by Bioz Stars, 2026-10
    99/100 stars

    Images

    1) Product Images from "Preclinical antiviral study of a liver-targeted TLR1/2 agonist in an immune-competent mouse model of HBV infection"

    Article Title: Preclinical antiviral study of a liver-targeted TLR1/2 agonist in an immune-competent mouse model of HBV infection

    Journal: bioRxiv

    doi: 10.64898/2026.05.27.728102

    Six-weeks-old C57BL/6 male mice were mock-transduced or transduced with 10 11 ⍰vge of AAV-HBV 1.3 mer genotype D/serotype ayw for 31 days to allow establishment of chronic infection. At day-35, treatment cycles were started, after mice were evenly grouped according to viremia and HBsAg antigenemia. Mice (n⍰= ⍰7/group) were injected, at indicated days with vehicle (PBS), free/non vectorized Pam 3 CSK 4 at 100 μg/injection, NP-Pam 3 CSK 4 at 5 μg/shot, or NP-Pam 3 CSK 4 at 20 μg/shot. 3TC was administrated continously at approximately 100 mg/kg/day (in drinking water) between days-35 and 64 and days-79 and 90. Blood/serum was collected at indicated times (blood drop symbol). Mice were euthanized at 90 days post-transduction. The different readouts and used techniques for exploitation of blood and liver samples are indicated.
    Figure Legend Snippet: Six-weeks-old C57BL/6 male mice were mock-transduced or transduced with 10 11 ⍰vge of AAV-HBV 1.3 mer genotype D/serotype ayw for 31 days to allow establishment of chronic infection. At day-35, treatment cycles were started, after mice were evenly grouped according to viremia and HBsAg antigenemia. Mice (n⍰= ⍰7/group) were injected, at indicated days with vehicle (PBS), free/non vectorized Pam 3 CSK 4 at 100 μg/injection, NP-Pam 3 CSK 4 at 5 μg/shot, or NP-Pam 3 CSK 4 at 20 μg/shot. 3TC was administrated continously at approximately 100 mg/kg/day (in drinking water) between days-35 and 64 and days-79 and 90. Blood/serum was collected at indicated times (blood drop symbol). Mice were euthanized at 90 days post-transduction. The different readouts and used techniques for exploitation of blood and liver samples are indicated.

    Techniques Used: Transduction, Infection, Injection

    Related Articles

    High Molecular Weight:

    Article Title: Patterns and trajectories of peripheral inflammatory cytokines, immune tolerance, and lymphocyte differentiation predict transition from acute to chronic low back pain in a sex and age specific manner
    Article Snippet: .. Prior to thawing PBMCs, wells of a 96-well plate were pre-loaded with 50μl RPMI-10 containing nothing (Mock); 100ng PAM 3 CSK 4 (TLR1/2 ligand, Invivogen); 10ng lipopolysaccharide (LPS, TLR4 ligand, Invivogen); 100ng R848 (TLR7/8 ligand, Invivogen); high molecular weight poly I:C-lyovec (MDA5 ligand, Invivogen); ISD-lyovec (cGAS-STING activator, Invivogen); 500ng mouse anti-human CD40 antibody (αCD40, R&D systems MAB6321) with 2μg goat anti-mouse IgG antibody (Jackson ImmunoResearch, for crosslinking); or 200ng anti-CD3 antibody (BioLegend), 200ng Ultra-Leaf anti-CD28 antibody (BioLegend), with 1.6μg goat anti-mouse IgG (for crosslinking). .. After thawing and treating PBMCs with DNAse as described for ‘flow cytometry analyses’ above, cells were counted using a Countess II with trypan blue exclusion (Thermo-Fisher) and 5×10 4 viable PBMCs in 50μl RPMI-10 were added to wells containing each of the 8 conditions.

    other:

    Article Title: DNA from Lactobacillus paragasseri SBT2055 Activates Plasmacytoid Dendritic Cells and Induces IFN-α via TLR9
    Article Snippet: Human PBMCs from healthy donors were obtained from Lonza (Basel, Switzerland).

    Article Title: Toll-like receptor 1 polymorphism is associated with impaired immune tolerance, dysregulated inflammatory responses to Borrelia burgdorferi , and heightened risk of post-infectious Lyme arthritis
    Article Snippet: WT THP-1 cells, TLR1-Knockout (KO) THP-1 cells (Ubigene), and TLR2-KO THP-1 cells (InvivoGen) were grown to ~80% confluency in 96-well tissue culture plates (2x10 5 /well) at 37°C, 5% CO 2 in cell-culture medium, then differentiated into macrophages using 200nM phorbol 12-myristate 13-acetate (PMA; Sigma-Aldrich).

    Enzyme-linked Immunosorbent Assay:

    Article Title: Trans-kingdom conservation of mechanism between bacterial actifensin and eukaryotic defensins
    Article Snippet: PBMCs were pre-stimulated with either actifensin (10 μM) or LL-37 (10 μM; tlrl-l37-5, InvivoGen, Toulouse, France) for 30 min. .. Afterwards, cells were stimulated with Pam 3 CSK 4 (tlrl-pms-1, InvivoGen, Toulouse, France), LPS (tlrl-3pelps, InvivoGen, Toulouse, France), or S. aureus RN4220 for 3 h. Cell-free culture supernatants were collected and analysed for cytokine release using a TNF ELISA kit (88-7346-88, Thermo Fisher Scientific, Darmstadt, Germany). .. One ml concentrated RBCs were diluted 1:10 in PBS pH 7.2 (Gibco) and centrifuged at 2000 × g for 10 min.



    Similar Products

    pam 3 csk 4  (InvivoGen)
    99
    InvivoGen pam 3 csk 4
    Six-weeks-old C57BL/6 male mice were mock-transduced or transduced with 10 11 ⍰vge of AAV-HBV 1.3 mer genotype D/serotype ayw for 31 days to allow establishment of chronic infection. At day-35, treatment cycles were started, after mice were evenly grouped according to viremia and HBsAg antigenemia. Mice (n⍰= ⍰7/group) were injected, at indicated days with vehicle (PBS), free/non vectorized <t>Pam</t> <t>3</t> <t>CSK</t> <t>4</t> at 100 μg/injection, NP-Pam 3 CSK 4 at 5 μg/shot, or NP-Pam 3 CSK 4 at 20 μg/shot. 3TC was administrated continously at approximately 100 mg/kg/day (in drinking water) between days-35 and 64 and days-79 and 90. Blood/serum was collected at indicated times (blood drop symbol). Mice were euthanized at 90 days post-transduction. The different readouts and used techniques for exploitation of blood and liver samples are indicated.
    Pam 3 Csk 4, supplied by InvivoGen, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/pam+3+csk+4/Pam3CSK4/bio_rxiv__64898__2026__05__27__728102-37-1-5
    Average 99 stars, based on 1 article reviews
    pam 3 csk 4 - by Bioz Stars, 2026-10
    99/100 stars
    		  Buy from Supplier
    tlr1 2 ligand pam 3 csk 4  (InvivoGen)
    99
    InvivoGen tlr1 2 ligand pam 3 csk 4
    Six-weeks-old C57BL/6 male mice were mock-transduced or transduced with 10 11 ⍰vge of AAV-HBV 1.3 mer genotype D/serotype ayw for 31 days to allow establishment of chronic infection. At day-35, treatment cycles were started, after mice were evenly grouped according to viremia and HBsAg antigenemia. Mice (n⍰= ⍰7/group) were injected, at indicated days with vehicle (PBS), free/non vectorized <t>Pam</t> <t>3</t> <t>CSK</t> <t>4</t> at 100 μg/injection, NP-Pam 3 CSK 4 at 5 μg/shot, or NP-Pam 3 CSK 4 at 20 μg/shot. 3TC was administrated continously at approximately 100 mg/kg/day (in drinking water) between days-35 and 64 and days-79 and 90. Blood/serum was collected at indicated times (blood drop symbol). Mice were euthanized at 90 days post-transduction. The different readouts and used techniques for exploitation of blood and liver samples are indicated.
    Tlr1 2 Ligand Pam 3 Csk 4, supplied by InvivoGen, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/pam+3+csk+4/Pam3CSK4/pmc12506935-305-81-89
    Average 99 stars, based on 1 article reviews
    tlr1 2 ligand pam 3 csk 4 - by Bioz Stars, 2026-10
    99/100 stars
    		  Buy from Supplier

    Image Search Results


    Six-weeks-old C57BL/6 male mice were mock-transduced or transduced with 10 11 ⍰vge of AAV-HBV 1.3 mer genotype D/serotype ayw for 31 days to allow establishment of chronic infection. At day-35, treatment cycles were started, after mice were evenly grouped according to viremia and HBsAg antigenemia. Mice (n⍰= ⍰7/group) were injected, at indicated days with vehicle (PBS), free/non vectorized Pam 3 CSK 4 at 100 μg/injection, NP-Pam 3 CSK 4 at 5 μg/shot, or NP-Pam 3 CSK 4 at 20 μg/shot. 3TC was administrated continously at approximately 100 mg/kg/day (in drinking water) between days-35 and 64 and days-79 and 90. Blood/serum was collected at indicated times (blood drop symbol). Mice were euthanized at 90 days post-transduction. The different readouts and used techniques for exploitation of blood and liver samples are indicated.

    Journal: bioRxiv

    Article Title: Preclinical antiviral study of a liver-targeted TLR1/2 agonist in an immune-competent mouse model of HBV infection

    doi: 10.64898/2026.05.27.728102

    Figure Lengend Snippet: Six-weeks-old C57BL/6 male mice were mock-transduced or transduced with 10 11 ⍰vge of AAV-HBV 1.3 mer genotype D/serotype ayw for 31 days to allow establishment of chronic infection. At day-35, treatment cycles were started, after mice were evenly grouped according to viremia and HBsAg antigenemia. Mice (n⍰= ⍰7/group) were injected, at indicated days with vehicle (PBS), free/non vectorized Pam 3 CSK 4 at 100 μg/injection, NP-Pam 3 CSK 4 at 5 μg/shot, or NP-Pam 3 CSK 4 at 20 μg/shot. 3TC was administrated continously at approximately 100 mg/kg/day (in drinking water) between days-35 and 64 and days-79 and 90. Blood/serum was collected at indicated times (blood drop symbol). Mice were euthanized at 90 days post-transduction. The different readouts and used techniques for exploitation of blood and liver samples are indicated.

    Article Snippet: Either Pam 3 CSK 4 (InvivoGen, USA) or the near-infrared fluorescent probe DiR XenoLight Dye (λ excitation = 750 nm, λ emission = 770 nm) (Perkin Elmer, USA) was incorporated during the nanoprecipitation.

    Techniques: Transduction, Infection, Injection